Research Study

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Principal Investigator 
Heather J. Sutherland

Overview

Body Locations and Systems 
Blood
Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
NCT03110562
Status 
Recruiting
Study Start/End 
Jul 25, 2017 to Jan 1, 2027
Locations 
Vancouver General Hospital
Name/Title 
Nasim Lowlaavar/Clinical Research Coordinator
Phone 
604-875-4111 Ext: 61971
Purpose of Study 

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. After progressive disease (PD), patients in the Vd Arm may cross over to SVd treatment. Patients who cross over will be referred to as SVdX patients.

Eligibility 

See Clinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.